Elotuzumab fails late-stage multiple myeloma trial (ELOQUENT-1)

Combination of elotuzumab plus lenalidomide and dexamethasone vs. lenalidomide and dexamethasone alone in patients with newly diagnosed, previously untreated multiple myeloma who are transplant-ineligible did not meet progression-free survival endpoint

Source:

Biospace Inc.